Alys Pharmaceuticals

Alys Pharmaceuticals is an immuno-dermatology focused company dedicated to redefining the treatment landscape for skin conditions. Founded in February 2024 with $100 million in financing from Medicxi, Alys is comprised of six subsidiary companies, each specializing in specific dermatology indications. Their diverse pipeline includes over a dozen active programs targeting a wide range of conditions, from atopic dermatitis and vitiligo to mastocytosis and cutaneous T-cell lymphoma. Alys's commitment to innovation, collaboration, and scientific expertise positions them as a leading force in developing transformative solutions for patients worldwide.

Alys boasts a strong leadership team comprised of world-leading dermatology experts and scientists from renowned institutions such as UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, and Georgia Institute of Technology. Their goal is to leverage cutting-edge technologies like siRNA and photoimmunotherapy to bring forward new modalities for treating a broad spectrum of dermatological conditions. Alys's dedication to research and development, along with its robust pipeline and collaborative approach, makes it a company with the potential to significantly impact the future of dermatological treatment.

Alys Pharmaceuticals is an R&D-focused immuno-dermatology company dedicated to redefining the treatment landscape for dermatological conditions by delivering innovative, transformative solutions to patients worldwide. They aim to achieve this through a robust pipeline of over a dozen active programs enabled by multi-platform technologies. Their mission is to address both established and underserved indications, including atopic dermatitis, vitiligo, alopecia areata, chronic spontaneous urticaria, CTCL, mastocytosis, and the prevention of dermatological side effects from oncology therapies.

Alys Pharmaceuticals promotes a collaborative and innovative culture, emphasizing a shared vision for advancing immuno-dermatology. The company is structured around its various subsidiary companies, allowing each to retain operational autonomy while benefiting from the expertise of the overarching Alys scientific leadership team. This approach fosters a culture of shared knowledge and expertise, encouraging cross-collaboration and the pursuit of cutting-edge scientific advancements. The company values a high level of scientific rigor and a commitment to bringing transformative solutions to patients worldwide.